npj Breast Cancer - Dynamic single-cell systemic immune responses in immunotherapy-treated early-stage HR+ breast cancer patients

Hematopoietic stem cells (HSCs) differentiate into multiple lineages, with such capacity impacted by aging. Here the authors identify Kitlo HSCs as a functionally distinct population that exhibits dis...

Therapeutic T cells engineered to recognize tumour antigens are frequently short-lived and acquire unfavourable phenotypes in tumours. Here authors show that a tandem approach using autologous T cells...

The mechanism of macrophage cytotoxicity against cancer cells requires further illustration. By employing CRISPR screening in CAR-macrophage and cancer cell co-culture system, the authors identify dep...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to prevent, and even reverse, immune checkpoint inhibitor–induced type 1 diabetes, ...

Karen Knudsen is leading Sean Parker's cancer immunotherapy incubator where philanthropy and venture capital meet.

The annual ASCO meeting sets the agenda for the year’s conversations around cancer treatment. We’ll review new data readouts, scrutinize pipelines, and take stock of the pathways ahead for oncology re...

PICI’s contributions at ASCO 2025 span more than 50 presentations, including 16 oral sessions, 30+ poster sessions, 10 e-papers and a featured clinical science symposium. This volume reflects not only...

Serotonin transporter (SERT) inhibits CD8 T cell antitumor immunity by depleting intratumoral serotonin. SERT-blocking selective serotonin reuptake inhibitor (SSRI) antidepressants enhance CD8 T cell ...

May 22, 2025 | 1:00PM - 8:00 PM ET MassBio Hub | 700 Tech Square 5th floor, Cambridge, MA Reception | Catalyst Restaurant

Background Immune checkpoint inhibitors (ICIs) have led to enduring responses in subsets of patients with cancer. However, these responses carry the risk of immune-related adverse events (irAEs), whic...

Background Immune checkpoint inhibitors (ICIs) have led to enduring responses in subsets of patients with cancer. However, these responses carry the risk of immune-related adverse events (irAEs), whic...

Patients with some gastrointestinal tumors were able to be treated with immunotherapy drugs alone and avoid surgery, chemotherapy or radiation, the study found.

Scientific Reports - LOXHD1 is an oncofusion-regulated antigen of ewing sarcoma

Abstract. The optimal means to prime for effective anti-tumor immunity in a cancer patient remains elusive in the current era of checkpoint blockade. Crafting a strategy to amplify CD8+ T cells while ...

With a new key hire, the Napster cofounder’s cancer fighting non-profit is ready to back the science both governments and markets leave behind.